Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PVCT $1.00 0.1399 +16.27%
ONCY $0.82 0.1020 +14.21%
BIND $8.94 1.1100 +14.18%
INCY $64.18 6.3100 +10.90%
XLRN $38.24 3.5000 +10.07%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CNDO $1.70 -0.1000 -5.56%
AEZS $1.06 -0.0500 -4.50%
ARGS $9.66 -0.3600 -3.59%
APRI $1.58 -0.0500 -3.07%
CRIS $1.27 -0.0400 -3.05%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Amgen, Sanofi, Ono Link with Academia on Proteins Project

(Reuters) Oct 28, 2014 - U.S.-based Amgen, France's Sanofi and Ono Pharmaceutical of Japan have linked with three research institutes to study a super-family of proteins controlling everything from taste to the spread of cancer.
read article 

AACR Congratulates Newest Institute of Medicine Members

(AACR) Oct 23, 2014 - The American Association for Cancer Research (AACR) congratulates its members who have been elected to the Institute of Medicine (IOM).
read press release 

City of Hope Announces New Hematologic Malignancies and Stem Cell Transplantation Institute

(City of Hope) Oct 27, 2014 - New institute attracts nationally known experts; wave of novel trials now underway for treatment of lymphoma, myeloma and leukemia.
read press release 

Yale and Gilead Sciences Extend Cancer Research Collaboration

(Yale News) Oct 23, 2014 - The Yale School of Medicine has announced a three-year extension of a research collaboration with Gilead Sciences, Inc., which was formed in 2011 to discover novel cancer therapies.
read article 

MolecularMatch Announces Innovative Solution to Connect Cancer Patients with the Most Effective Treatments and Clinical Trials

(MolecularMatch) Oct 27, 2014 – Today, MolecularMatch, Inc. announced it has launched its innovative software solution as an open Beta information service for oncologists and patients to easily connect cancer patients with the most appropriate FDA-approved treatments and clinical trials based on the molecular make-up of the patient’s disease.
read corporate press release 

N-of-One Selected by Intermountain Healthcare to Provide Deep Clinical Interpretation for Cancer Genomics

( Oct 28, 2014 - N-of-One, Inc., the leading provider of clinical interpretation for precision medicine in oncology, today announced an agreement with Intermountain Healthcare to provide clinical interpretation to Intermountain Healthcare as a key component of Intermountain’s precision medicine services for oncology.
read article 

U.S. Judge Slashes $9 Billion Award vs Takeda, Lilly Over Diabetes Drug

(Reuters) Oct 27, 2014 - A U.S. judge on Monday slashed a $9 billion punitive damages award to $36.8 million against Takeda Pharmaceutical Co and Eli Lilly & Co over their Actos diabetes drug, although she rejected their request for a new trial.
read article 

Burnout Reported by Most Palliative Care Clinicians

(HCPLive/HealthDay) Oct 28, 2014 - More than 60 percent of palliative care clinicians report burnout, according to a study presented at the American Society of Clinical Oncology's inaugural Palliative Care in Oncology Symposium, held from Oct. 24 to 25 in Boston.
read article 

Ventana Announces Collaboration to Develop Companion Diagnostics for ImmunoGen's Targeted Anticancer Agents

(Yahoo! Finance) Oct 28, 2014 - Ventana Medical Systems, Inc., a member of the Roche Group, today announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates.
read article 

Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy

(Bristol-Myers Squibb) Oct 28, 2014 - Bristol-Myers Squibb Company and F-star Alpha Ltd. today announced that the companies, together with the F-star Alpha Ltd. shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire F-star Alpha Ltd, and gain worldwide rights to its lead asset FS102.
read corporate press release 

Higher Copayments Are Associated with Discontinuation of Aromatase Inhibitors

(PRWeb) Oct 27, 2014 - Discontinuation and nonadherence were higher among breast cancer patients taking brand name aromatase inhibitors (BAIs) vs generic AIs (GAIs), according to a new study published October 27 in the JNCI: Journal of the National Cancer Institute.
read press release 

PSA Test Should be Abandoned as Screen for Prostate Cancer, Task Force Says

(CBC News) Oct 27, 2014 - The blood test mostly commonly used to screen men for prostate cancer should be dropped, because it can result in more harm than good, says a Canadian task force.
read article 

Bad Tumor Markers Equal to Bad Drugs

(MedPage Today) Oct 27, 2014 - Approval process for cancer biomarker tests is not as stringent as for drugs, but should be.
read article (free registration required) 

Heat Biologics, Inc. Commences Patient Dosing of Phase 2 Clinical Study of Vesigenurtacel-L for the Treatment of Bladder Cancer

(TheStreet) Oct 27, 2014 - Heat Biologics, Inc., a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that it has initiated patient dosing in its Phase 2 clinical trial of vesigenurtacel-L (HS-410) in subjects with high-risk, non-muscle invasive bladder cancer.
read article 

Celator(R) Pharmaceuticals Announces Phase 3 Clinical Study of CPX-351 Achieved Target Enrollment in High Risk (Secondary) Acute Myeloid Leukemia

(CNNMoney) Oct 27, 2014 - Celator Pharmaceuticals, Inc. today announced that the target enrollment of 300 patients has been achieved in the company's multicenter, randomized, open-label Phase 3 study of CPX-351 (cytarabine:daunorubicin) Liposome for Injection versus the current standard of care, conventional cytarabine and daunorubicin therapy (7+3) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML).
read article 

Reminders May Trigger Advance Care Conversations Earlier

(Medscape Medical News) Oct 28, 2014 - A simple trigger reminder to oncologists at key times during the course of care of a seriously ill cancer patient may prompt earlier discussions regarding advance care planning (ACP) for the end-of-life phase, according to preliminary research presented at the inaugural Palliative Care in Oncology Symposium, held in Boston, Massachusetts, October 24-25.
read article (free registration required) 

'Prehabilitation' Before Colon Cancer Surgery May Aid Recovery

(U.S. News & World Report/HealthDay News) Oct 27, 2014 - Exercising, eating a healthy diet and learning relaxation techniques before colorectal cancer surgery appeared to speed a patient's recovery, a small study found.
read article 

Pain Intensity Can Predict Head and Neck Cancer Survival

(American Pain Society) Oct 27, 2014 — Pre-treatment pain intensity is an independent survival predictor for patients with head and neck cancer, according to new research published in The Journal of Pain.
read press release 

Laparoscopic Renal Cryoablation Effective for Small RCCs

(medwireNews) Oct 27, 2014 - Study findings support the primary use of laparoscopic renal cryoablation (LRC) for long-term disease control in patients with a newly diagnosed single clinical T1a small renal mass (SRM).
read article 

Screening with Tomosynthesis and Mammography Is Cost-Effective

(RSNA) Oct 28, 2014 - Adding tomosynthesis to biennial digital mammography screening for women with dense breasts is likely to improve breast cancer detection at a reasonable cost relative to biennial mammography screening alone, according to a new study published online in the journal Radiology.
read press release 

Obesity Linked to Worst Outcomes in Children With ALL

(Medscape Medical News) Oct 27, 2014 - Obese children with B-cell acute lymphocytic leukemia (ALL) have significantly worse outcomes following induction chemotherapy compared with their lean counterparts, researchers report.
read article (free registration required) 

Genetic Tests Dominate Thyroid Meeting

(MedPage Today) Oct 27, 2014 - The competition for top genetic test for indeterminate thyroid nodules continues at this year's American Thyroid Association meeting.
read article (free registration required) 

Study May Explain Why Targeted Drug Doesn't Benefit Patients With Early-Stage Lung Cancer

(OSUCCC - James) Oct 26, 2014 - The drug erlotinib is highly effective in treating advanced-stage lung cancer patients whose tumors have a particular gene change, but when the same drug is used for patients with early-stage tumors with the same gene change, they actually fare worse than if they took nothing.
read press release 

Therapy Treats Lung Cancer Based on Patients’ Genetic Markers

(San Francisco Chronicle) Oct 28, 2014 - A new type of clinical trial for lung cancer patients getting under way at hospitals in the Bay Area and around the country may change the way drugs are tested in the future.
read article 

Hospitals Furious at Cancer-Drug Price Hikes

(TIME) Oct 27, 2014 - Some of the nation's hospitals are seriously ticked off at Genentech, the San Francisco biotech firm, for implementing a stealth price hike for three critical cancer drugs.
read article